Log inSign up
Image
user avatar
BridgeBio Pharma
@BridgeBioPharma
We move at the speed of patient need. We exist to bring meaningful medicines to people living with genetic conditions. $BBIO
Palo Alto, California
bridgebio.com
Joined January 2021
165
Following
2,032
Followers
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Nov 23, 2024
    We are excited to announce that the U.S. FDA approved our orally-administered near-complete (≥90%) stabilizer of TTR for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). We are proud of the opportunity to serve patients within this community.
    Image
    00:00
    44K
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Oct 31, 2023
    In honor of Dwarfism Awareness Month, we heard from Sean, living w/ achondroplasia, a rare, genetic condition that affects bone growth. Hear his story about growing up with achondroplasia & how his friendships & exercising provide a great outlet for him. bit.ly/3Q2AE3A
    Image
    00:00
    7.7K
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Feb 11, 2022
    ~10,000 people are diagnosed each year in the U.S. with bile duct cancer, also known as cholangiocarcinoma (CCA). On #WorldCCADay, we raise awareness about this cancer so that all can #SeeCCA and work to improve the quality of life of patients globally. bit.ly/3G2VVmK
    Image
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Jul 17, 2023
    We’re thrilled to share results from our ATTRibute-CM Phase 3 clinical trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). Thank you to the patients, families, and healthcare providers who have made this study possible. bit.ly/44OjFHQ
    Image
    4.2K
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Apr 7, 2025
    More than 200,000 of children’s lives have been saved by a vital FDA program that incentivizes rare pediatric disease drug development; however, it expired last December. In a @statnews First Opinion piece, BridgeBio CEO Neil Kumar, Ph.D., urges Congress to reauthorize the
    Image
    229K
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    May 28, 2021
    We are proud to share we received FDA approval for our therapy for FGFR2 fusion+, previously treated, advanced CCA. Thank you to the CCA patient community and their families, along with every physician, scientist, and advocate who made this possible. bit.ly/3hVzJ5E $BBIO
    Image
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Mar 16, 2021
    We are BridgeBio Pharma, a company founded to discover, create, test and deliver breakthrough medicines for patients with genetic diseases as quickly and safely as possible. Hear more about our mission to target genetic diseases at their source. bridgebio.com/about
    Image
    00:00
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Jan 27, 2022
    We're honored to share we’ve dosed our first patient with CAH. This is the second gene therapy trial we've initiated in less than four months, and we're excited to advance this trial in the hope of providing a potential new option to patients. $BBIO bit.ly/35y6j9H
    Image
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Mar 14, 2022
    Today, we shared positive Phase 2 data from our limb-girdle muscular dystrophy type 2i (LGMD2i) trial. If successful, we believe our medicine could be the first approved therapy for the treatment of patients with LGMD2i. Read more about the data: bit.ly/3i3my1h $BBIO
    Image
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Mar 27, 2025
    We're thrilled to share that the Japanese Ministry of Health, Labour and Welfare has approved our near-complete (≥90%) stabilizer of transthyretin (TTR) for people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in Japan. There is significant need for new options
    Image
    902
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Aug 27, 2024
    We will present insights from ATTRibute-CM, our Phase 3 trial in patients with transthyretin amyloidosis, and its open-label extension at @ESCardio in a moderated poster session this year. Learn more: bit.ly/4dpzYzC
    Image
    20K
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Jul 31, 2023
    We’re thrilled to share that the first patient has been dosed in our Phase 3 FORTIFY clinical trial for LGMD2iI/R9. If successful, BBP-418 has the potential to address serious unmet needs for LGMD2I/R9, a rare progressive neuromuscular condition. bit.ly/44LhFAQ
    Image
    929
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Dec 5, 2023
    We’re thrilled to share we have submitted our NDA to the U.S. FDA for acoramidis for patients with ATTR-CM. We extend our appreciation to the patients in our clinical trials, their families, our investigators, and our team who helped make this possible. bit.ly/46IBOYm
    Image
    3.6K
  • user avatar
    BridgeBio Pharma
    @BridgeBioPharma
    Oct 4, 2023
    Canavan disease is an ultra-rare & fatal condition with no approved therapies. October is Canavan Awareness Month, & in recognition, we'd like to highlight Dr. Guangping Gao who has contributed trailblazing work in the field of AAV gene therapy. Watch: bit.ly/3LMZq6y
    Image
    00:00
    2.3K